

IAP5 Rec'd PCT/PTO 26 SEP 2006

Docket No.: 66339(45579)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10/594360

In re Patent Application of:
Patrizia Cali et al.

Application No.: National Phase of
PCT/DK2005/000201

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: PEPTIDE DEFORMYLASE INHIBITORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "Documents Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be

IAP5 Rec'd PCT/PTO 26 SEP 2006

Application No.: National Phase of PCT/DK2005/000201 2 Docket No.: 66339(45579)

10/594360

an admission that any patent, publication or other information referred to therein is
"prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with
37 CFR 1.98 and the Examiner is respectfully requested to consider the listed
documents.

The Director is hereby authorized to charge any deficiency in the fees filed,
asserted to be filed or which should have been filed herewith (or with any paper
hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under
Order No. 66339(45579).

Dated: September 26, 2006

Respectfully submitted,

By 

Peter F. Corless

Registration No.: 33,860

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Patrizia Cali
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	66339(45579)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-2002/070540-A2	09-12-2002	SmithKline Beecham Corporation		
	BB	WO-2002/102791-A1	12-27-2002	Vicuron Pharmaceuticals, Inc.		
	BC	WO-2002/28829-A2	04-11-2002	Questcor Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

10/594360

FEE SUMMARY SHEET

Transmittal to US Designated-Elected Office

Date: September 26, 2006
Time: 5:09 PM
Docket: 66339(45579)

Filing Date: Concurrently Herewith
Application No: Not Yet Assigned
Total Fee: \$ 1,030.00

Code	Amount	37 CFR	Fee Description	Listed on
1631	300.00	1.492(a)	Basic National Stage fee	Transmittal to US Designated-Elected Office (PTO 1390)
1633	200.00	1.492(c)(2)	National Stage Examination Fee - all other situations	Transmittal to US Designated-Elected Office (PTO 1390)
1642	400.00	1.492(b)(3)	National Stage Search Fee - search report prepared and provided to USPTO	Transmittal to US Designated-Elected Office (PTO 1390)
1617	130.00	1.492(h)	Search fee, examination fee or oath or declaration after thirty months from priority date	Transmittal to US Designated-Elected Office (PTO 1390)